353 related articles for article (PubMed ID: 34188445)
1. Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.
Hussain RM; Shaukat BA; Ciulla LM; Berrocal AM; Sridhar J
Drug Des Devel Ther; 2021; 15():2653-2665. PubMed ID: 34188445
[TBL] [Abstract][Full Text] [Related]
2. Innovative therapies for neovascular age-related macular degeneration.
Al-Khersan H; Hussain RM; Ciulla TA; Dugel PU
Expert Opin Pharmacother; 2019 Oct; 20(15):1879-1891. PubMed ID: 31298960
[No Abstract] [Full Text] [Related]
3. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Hussain RM; Ciulla TA
Expert Opin Emerg Drugs; 2017 Sep; 22(3):235-246. PubMed ID: 28756707
[TBL] [Abstract][Full Text] [Related]
4. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020.
Samanta A; Aziz AA; Jhingan M; Singh SR; Khanani AM; Chhablani J
Asia Pac J Ophthalmol (Phila); 2020; 9(3):250-259. PubMed ID: 32511123
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
Campochiaro PA; Avery R; Brown DM; Heier JS; Ho AC; Huddleston SM; Jaffe GJ; Khanani AM; Pakola S; Pieramici DJ; Wykoff CC; Van Everen S
Lancet; 2024 Apr; 403(10436):1563-1573. PubMed ID: 38554726
[TBL] [Abstract][Full Text] [Related]
6. Abicipar pegol for neovascular age-related macular degeneration.
Hussain RM; Weng CY; Wykoff CC; Gandhi RA; Hariprasad SM
Expert Opin Biol Ther; 2020 Sep; 20(9):999-1008. PubMed ID: 32552072
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
Nair AA; Finn AP; Sternberg P
Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
[TBL] [Abstract][Full Text] [Related]
9. Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration.
Ferro Desideri L; Traverso CE; Nicolò M
Expert Opin Investig Drugs; 2020 Jul; 29(7):651-658. PubMed ID: 32479126
[TBL] [Abstract][Full Text] [Related]
10. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
Callanan D; Kunimoto D; Maturi RK; Patel SS; Staurenghi G; Wolf S; Cheetham JK; Hohman TC; Kim K; López FJ; Schneider S
J Ocul Pharmacol Ther; 2018 Dec; 34(10):700-709. PubMed ID: 30412448
[No Abstract] [Full Text] [Related]
11. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST; Patel S
Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.
Dugel PU; Boyer DS; Antoszyk AN; Steinle NC; Varenhorst MP; Pearlman JA; Gillies MC; Finger RP; Baldwin ME; Leitch IM
Ophthalmol Retina; 2020 Mar; 4(3):250-263. PubMed ID: 31924544
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
[TBL] [Abstract][Full Text] [Related]
16. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
Jaffe GJ; Ciulla TA; Ciardella AP; Devin F; Dugel PU; Eandi CM; Masonson H; Monés J; Pearlman JA; Quaranta-El Maftouhi M; Ricci F; Westby K; Patel SC
Ophthalmology; 2017 Feb; 124(2):224-234. PubMed ID: 28029445
[TBL] [Abstract][Full Text] [Related]
17. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.
Nicolò M; Ferro Desideri L; Vagge A; Traverso CE
Expert Opin Investig Drugs; 2021 Mar; 30(3):193-200. PubMed ID: 33471572
[TBL] [Abstract][Full Text] [Related]
18. [Modern trends in anti-VEGF therapy for age-related macular degeneration].
Budzinskaya MV; Plyukhova AA; Alkharki L
Vestn Oftalmol; 2023; 139(3. Vyp. 2):46-50. PubMed ID: 37144368
[TBL] [Abstract][Full Text] [Related]
19. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Khanani AM; Callanan D; Dreyer R; Chen S; Howard JG; Hopkins JJ; Lin CY; Lorenz-Candlin M; Makadia S; Patel S; Tam T; Gune S;
Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618
[TBL] [Abstract][Full Text] [Related]
20. Wet age-related macular degeneration: treatment advances to reduce the injection burden.
Baumal CR
Am J Manag Care; 2020 May; 26(5 Suppl):S103-S111. PubMed ID: 32479026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
